Suppr超能文献

新冠病毒感染中免疫细胞的功能:基于细胞疗法的发展

Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics.

作者信息

Sayahinouri Maryam, Mashayekhi Firouz Sahar, Ebrahimi Sadrabadi Amin, Masoudnia Mina, Abdolahi Mahnaz, Jafarzadeh Fatemeh, Nouripour Meshkat, Mirzazadeh Sana, Zangeneh Nazanin, Jalili Arsalan, Aghdami Nasser

机构信息

Department of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Parvaz Research Ideas Supporter Institute, Tehran, Iran.

出版信息

Bioimpacts. 2023;13(2):159-179. doi: 10.34172/bi.2023.23839. Epub 2023 Jan 28.

Abstract

In late December 2019, a sudden severe respiratory illness of unknown origin was reported in China. In early January 2020, the cause of COVID-19 infection was announced a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Examination of the SARS-CoV-2 genome sequence revealed a close resemblance to the previously reported SARS-CoV and coronavirus Middle East respiratory syndrome (MERS-CoV). However, initial testing of drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. One of the key strategies to fight the virus is to look at how the immune system works against the virus, which has led to a better understanding of the disease and the development of new therapies and vaccine designs. This review discussed the innate and acquired immune system responses and how immune cells function against the virus to shed light on the human body's defense strategies. Although immune responses have been revealed critical to eradicating infections caused by coronaviruses, dysregulated immune responses can lead to immune pathologies thoroughly investigated. Also, the benefit of mesenchymal stem cells, NK cells, Treg cells, specific T cells, and platelet lysates have been submitted as promising solutions to prevent the effects of infection in patients with COVID-19. It has been concluded that none of the above has undoubtedly been approved for the treatment or prevention of COVID-19, but clinical trials are underway better to understand the efficacy and safety of these cellular therapies.

摘要

2019年12月下旬,中国报告了一种病因不明的突发严重呼吸系统疾病。2020年1月初,宣布新型冠状病毒肺炎(COVID-19)感染的病因是一种名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新型冠状病毒。对SARS-CoV-2基因组序列的检测显示,它与先前报告的SARS-CoV和中东呼吸综合征冠状病毒(MERS-CoV)极为相似。然而,最初针对SARS-CoV和MERS-CoV使用的药物测试在控制SARS-CoV-2方面并未取得成效。对抗该病毒的关键策略之一是研究免疫系统如何对抗病毒,这有助于更好地了解该疾病,并推动新疗法和疫苗设计的发展。 本综述讨论了先天性和获得性免疫系统反应,以及免疫细胞如何对抗病毒,以阐明人体的防御策略。 虽然免疫反应已被证明对根除冠状病毒引起的感染至关重要,但失调的免疫反应可能导致免疫病理学,对此需进行深入研究。此外,间充质干细胞、自然杀伤细胞、调节性T细胞、特定T细胞和血小板裂解物的益处已被提出,有望作为预防COVID-19患者感染影响的解决方案。 得出的结论是,上述任何一种方法都尚未被明确批准用于治疗或预防COVID-19,但相关临床试验正在进行,以更好地了解这些细胞疗法的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7dd/10182441/dd95538b16a1/bi-13-159-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验